ImmuPharma PLC
  • Announcements
  • About Us
    • About Us
    • Our Team
    • Board of Directors
  • Our Science
    • Our Science
    • ImmuPharma Biotech
    • Key Clinical Investigators
  • Pipeline
    • Pipeline
    • Autoimmunity & Inflammation
    • Anti-Infectives
  • Partnerships & Collaborations
  • Investors
    • Investors
    • AIM Rule 26 Information
    • Regulatory News
    • Corporate Governance
    • Board of Directors
    • Annual Reports
    • Analyst Research
    • Interviews
    • Professional advisers
    • Email Alerts
  • Contact
Archives
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
September 06, 2023

Major shareholding from Lanstead Capital via TR1

Read More
August 31, 2023

Subscriptions to raise £1.35 million; Sharing Agreement; WRAP Retail Offer to raise up to £0.5 million • Related Party Transactions

Read More
August 31, 2023

WRAP Retail Offer for up to £500,000

Read More
August 31, 2023

INTERIM RESULTS for the six months ended 30 June 2023

Read More
August 21, 2023

Extension of Warrants in Incanthera plc

Read More
August 11, 2023

Board strengthened Ahead of next phase of company progression

Read More
July 02, 2023

2023 Result of Annual General Meeting – All Resolutions Passed

Read More
June 19, 2023

Phase 2/3 adaptive clinical trial of P140 (Lupuzor™) in Lupus to commence following FDA meeting

Read More
June 16, 2023

Immupharma PLC Warrants Outstanding

Read More
June 06, 2023

Notice of AGM & Annual Report & Accounts

Read More
May 11, 2023

TR1 Lanstead holding 10 May 2023

Read More
May 11, 2023

FINAL RESULTS ANNOUNCEMENT for the year ended 31 December 2022

Read More
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 16
  • Keep up-to-date with email alerts

  • @immupharma

Aim Rule 26 Contact informationDisclaimerPrivacy PolicySite map

© ImmuPharma PLC 2005-2022 | All rights reserved